Chinese Academy of Sciences Researchers Develop Biomimetic Bridge to Solve CAR T Cell Leukemia Therapy Relapse

Chinese Academy of Sciences develops a non genetic bridge to enhance CAR T cell therapy, targeting leukemia relapse and reducing side effects for patients.

By: AXL Media

Published: Mar 9, 2026, 11:30 AM EDT

Source: The information in this article was sourced from Chinese Academy of Sciences Headquarters

A Molecular Bridge for Resistant Malignancies

A breakthrough study published in Cell on March 9 reveals a novel biomimetic platform designed to overcome the primary cause of failure in chimeric antigen receptor T cell therapy. While CAR T treatments have revolutionized leukemia care, over half of all patients experience a relapse because cancer cells eventually hide or shed the specific antigens the engineered cells are programmed to find. To counter this, researchers at the Chinese Academy of Sciences developed the Ferritin Aggregation Cell Engager, or FACE, which acts as a physical reinforcement between the therapeutic T cells and their targets. According to the research team, this "molecular bridge" ensures that the immune system can identify and destroy leukemia cells even after they have evolved to evade traditional detection.

Bypassing the Costs of Genetic Engineering

Standard methods for improving CAR T efficacy typically involve complex and expensive secondary genetic modifications to the T cells themselves. The FACE platform diverges from this path by utilizing a self-assembling ferritin structure that binds to CD71, a protein heavily expressed on the surface of both leukemia cells and CAR T cells. According to Prof. Wei Wei, the corresponding author from the Institute of Process Engineering, this strategy can be seamlessly integrated into current manufacturing workflows as a simple culture supplement. By avoiding the need for further genetic engineering, the researchers have created a scalable and cost effective method to enhance cellular interaction, potentially lowering the technical barriers for clinics worldwide.

Superior Performance in Low Antigen Environments

In rigorous testing using patient-derived xenograft models, the FACE-enhanced cells demonstrated a remarkable ability to function with high efficiency at lower concentrations. The study found that these modified cells achieved the same therapeutic outcomes as conventional treatments while using only 20% of the standard cell dose. Crucially, the platform remained effective even when leukemia antigen expression dropped below 10% of normal levels, a threshold where standard CAR T therapies typically fail. According to the study findings, this heightened sensitivity resulted in a 100% survival rate in animal models, offering a potential solution for patients whose cancer has become near...